NDA 021361 · Salix Pharms
Xifaxan
Rifaximin · Oral · Rifamycin Antibacterial
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
May 25, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
212
56 Phase 3, 22 recruiting
FAERS reports
21,335
16,688 serious, 6,241 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2025.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: • Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older. ( 1.1 ) • Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. ( 1.2 ) • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ( 1.3 ) Limitations of Use TD: Should not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. ( 1.1, 5.1 ) 1.1 Travelers’ Diarrhea XIFAXAN is indicated for the treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adults and pediatric patients 12 years of age and older. Limitations of Use XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli [see Warnings and Precautions ( 5.1 ), Clinical Pharmacology ( 12.4 ), Clinical Studies ( 14.1 )]. 1.2 Hepatic Encephalopathy XIFAXAN is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. In the placebo-controlled trial of XIFAXAN for HE, 91% of the patients were using lactulose...
Mechanism: Rifaximin is an antibacterial drug [see Clinical Pharmacology ( 12.4 )].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2015 Supplement 12 · Efficacy · priority review LabelLetter
- May 25, 2004 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
2 products under this application
- XIFAXAN · RIFAXIMIN 550MG · TABLET, ORAL · Prescription · TE AB
- XIFAXAN · RIFAXIMIN 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rifaximin" as an intervention, any sponsor and status, largest first.
- Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment StudyPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01543178 · 2,583 participants · Start Feb 2012 · Primary completion Jun 2014
Drug: open-label rifaximin; double-blind placebo and 1 more · For: Irritable Bowel Syndrome With Diarrhea
Sites: Anniston, Alabama; Birmingham, Alabama; Dothan, Alabama · 296 sites in all
- Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's DiarrheaPivotal-lookingCompleted
Actavis Inc.Industry
NCT02498418 · 739 participants · Start Jan 6, 2016 · Primary completion Feb 28, 2017
Drug: Rifaximin; Xifaxan® and 1 more · For: Diarrhea
Sites: Coral Gables, Florida
- Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00328380 · 660 participants (planned) · Start Dec 2005 · Primary completion Dec 2006
Drug: Rifaximin · For: Diarrhea
Sites: South Miami, Florida; Houston, Texas; La Porte, Texas
- Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00724126 · 637 participants · Start Jul 2008 · Primary completion Aug 2009
Drug: Rifaximin; Placebo · For: Non-Constipation Irritable Bowel Syndrome
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 88 sites in all
- Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00731679 · 623 participants · Start Jul 2008 · Primary completion Aug 2009
Drug: Rifaximin; Placebo · For: Non-Constipation Irritable Bowel Syndrome
Sites: Hueytown, Alabama; Phoenix, Arizona; Sierra Vista, Arizona · 96 sites in all
- Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel SyndromePivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00269412 · 525 participants (planned) · Start Dec 2005 · Primary completion Aug 2007
Drug: Rifaximin · For: Irritable Bowel Syndrome
Sites: Scottsdale, Arizona; Tempe, Arizona; Anaheim, California · 67 sites in all
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05071716 · 524 participants · Start Apr 7, 2022 · Primary completion Dec 23, 2025
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Dothan, Alabama; Chandler, Arizona; Peoria, Arizona · 150 sites in all
- Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05297448 · 517 participants · Start Aug 3, 2022 · Primary completion Feb 24, 2026
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Homewood, Alabama; Chandler, Arizona; Sun City, Arizona · 188 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,264
- hospitalisation1,954
- diarrhoea1,258
- off label use1,176
- therapy interrupted1,176
- ammonia increased862
- nausea854
- hepatic encephalopathy836
- fatigue815
- drug ineffective752
- confusional state733
- insurance issue729
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 42 |
| 2006 | 71 |
| 2007 | 48 |
| 2008 | 31 |
| 2009 | 46 |
| 2010 | 81 |
| 2011 | 115 |
| 2012 | 177 |
| 2013 | 186 |
| 2014 | 294 |
| 2015 | 904 |
| 2016 | 1,653 |
| 2017 | 2,331 |
| 2018 | 1,477 |
| 2019 | 1,813 |
| 2020 | 1,958 |
| 2021 | 1,931 |
| 2022 | 1,771 |
| 2023 | 2,023 |
| 2024 | 1,640 |
| 2025 | 1,328 |
| 2026 | 1,404 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xifaxan (Rifaximin)
2024 spending
$1.16B
Beneficiaries
104,805
416,690 claims
Per beneficiary
$11,050
$54.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $844,562,189 |
| 2021 | $890,298,769 |
| 2022 | $969,541,694 |
| 2023 | $1,090,110,101 |
| 2024 | $1,158,111,409 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
Pose E, Jiménez C, Zaccherini G, et al. · JAMA 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Rifaximin treatment in hepatic encephalopathy.
Bass NM, Mullen KD, Sanyal A, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
Fu J, Gao Y, Shi L · PLoS One 2022 · Meta-Analysis, Systematic Review
- Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.
Gatta L, Scarpignato C · Aliment Pharmacol Ther 2017 · Meta-Analysis, Systematic Review
- Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis.
Wang J, Zhang L, Hou X · Expert Rev Gastroenterol Hepatol 2021 · Meta-Analysis, Systematic Review
- Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.
Ford AC, Harris LA, Lacy BE, et al. · Aliment Pharmacol Ther 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Salix Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.